These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28462918)

  • 1. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
    Long J; Fang WY; Chang L; Gao WH; Shen Y; Jia MY; Zhang YX; Wang Y; Dou HB; Zhang WJ; Zhu J; Liang AB; Li JM; Hu J
    Leukemia; 2017 Dec; 31(12):2761-2770. PubMed ID: 28462918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
    Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
    J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Myc suppresses miR-451⊣YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia.
    Su R; Gong JN; Chen MT; Song L; Shen C; Zhang XH; Yin XL; Ning HM; Liu B; Wang F; Ma YN; Zhao HL; Yu J; Zhang JW
    Oncotarget; 2016 Nov; 7(47):77430-77443. PubMed ID: 27764807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
    Leukemia; 2008 Dec; 22(12):2159-68. PubMed ID: 18784743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
    Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
    Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
    Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
    J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
    Harada T; Ohguchi H; Grondin Y; Kikuchi S; Sagawa M; Tai YT; Mazitschek R; Hideshima T; Anderson KC
    Leukemia; 2017 Dec; 31(12):2670-2677. PubMed ID: 28490812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
    Zhang P; Brinton LT; Williams K; Sher S; Orwick S; Tzung-Huei L; Mims AS; Coss CC; Kulp SK; Youssef Y; Chan WK; Mitchell S; Mustonen A; Cannon M; Phillips H; Lehman AM; Kauffman T; Beaver L; Canfield D; Grieselhuber NR; Alinari L; Sampath D; Yan P; Byrd JC; Blachly JS; Lapalombella R
    Clin Cancer Res; 2021 Apr; 27(8):2352-2366. PubMed ID: 33542077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
    Matthews GM; Mehdipour P; Cluse LA; Falkenberg KJ; Wang E; Roth M; Santoro F; Vidacs E; Stanley K; House CM; Rusche JR; Vakoc CR; Zuber J; Minucci S; Johnstone RW
    Blood; 2015 Nov; 126(21):2392-403. PubMed ID: 26447190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of Akt-mediated HDAC3 expression and CDK2 T39 phosphorylation by a bichalcone analog contributes to S phase retardation of cancer cells.
    Hung KC; Lin ML; Hsu SW; Lee CC; Huang RY; Wu TS; Chen SS
    Eur J Pharmacol; 2018 Jun; 829():141-150. PubMed ID: 29665367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.
    Zhang L; Hong Z; Zhang RR; Sun XZ; Yuan YF; Hu J; Wang X
    Biomed Pharmacother; 2016 Oct; 83():958-966. PubMed ID: 27522258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.
    Rajendran P; Kidane AI; Yu TW; Dashwood WM; Bisson WH; Löhr CV; Ho E; Williams DE; Dashwood RH
    Epigenetics; 2013 Jun; 8(6):612-23. PubMed ID: 23770684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular matrix stiffness causes systematic variations in proliferation and chemosensitivity in myeloid leukemias.
    Shin JW; Mooney DJ
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12126-12131. PubMed ID: 27790998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy.
    Brown KK; Montaser-Kouhsari L; Beck AH; Toker A
    Cell Rep; 2015 Jun; 11(9):1358-66. PubMed ID: 26027929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia.
    Wang L; You LS; Ni WM; Ma QL; Tong Y; Mao LP; Qian JJ; Jin J
    Leuk Res; 2013 Oct; 37(10):1329-40. PubMed ID: 23867056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition.
    Yin Y; Zhang M; Dorfman RG; Li Y; Zhao Z; Pan Y; Zhou Q; Huang S; Zhao S; Yao Y; Zou X
    Cell Death Dis; 2017 Jun; 8(6):e2856. PubMed ID: 28569784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
    Wells CE; Bhaskara S; Stengel KR; Zhao Y; Sirbu B; Chagot B; Cortez D; Khabele D; Chazin WJ; Cooper A; Jacques V; Rusche J; Eischen CM; McGirt LY; Hiebert SW
    PLoS One; 2013; 8(7):e68915. PubMed ID: 23894374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion.
    Bradley EW; Carpio LR; Westendorf JJ
    J Biol Chem; 2013 Apr; 288(14):9572-9582. PubMed ID: 23408427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.